Top 5 Medical Stocks To Buy For 2018


Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a platform of adenovirus vectors for delivering drugs and vaccines that dovetails nicely with its existing suite of gene therapy technologies, suggests John McCamant, editor of The Medical Technology Stock Letter.

The ability to increase the payloads of viral vectors so they can carry multiple genes and regulatory elements will expand the opportunity for gene therapy to treat a wide range of diseases.


XON continues to build out its broad gene therapy platform with various viral as well as non-viral transfer techniques at their disposal to pursue an array of in-vivo and ex-vivo gene and cell therapy approaches.

The substantial payload capacity and a helper-dependent adenoviral system will allow the company to pursue new drug development targets and will also provide more partnering opportunities.

Top 5 Medical Stocks To Buy For 2018: Microchip Technology Incorporated(MCHP)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Microchip Technology (MCHP) sunk to the bottom of the S&P 500 today as semiconductor stocks got clobbered.

    Getty Images

    Shares of Microchip Technology tumbled 7.5% to $61.23 today, while the S&P 500 declined 0.4% to 2,191.08. The SPDR S&P Semiconductor ETF (XSD) fell 4.8% to $52.29, while the VanEck Vectors Semiconductor ETF (SMH) dropped 4.8% to $67.68.

    Today’s slaughter comes two days after Microchip Technology narrowed its third-quarter guidance. Stifel’s Kevin Cassidy and team had the details:


    Microchip upwardly revised its December ending quarter…Non-GAAP EPS guidance was updated to $0.87 – $0.94 compared to $0.85 – $0.95 previously…The According to management, the upside is coming from better than expected integration of recent acquisitions. Management pointed out that significant gross margin improvements may be recognized as the inventory of higher cost products from the now closed Micrel fab is depleted. We have revised our revenue and non-GAAP earnings estimates and increased our 12-month target price to $70.

    Microchip Technology’s market capitalization fell to $13.2 billion from $14.3 billion yesterday. It report net income of $324 million on sales of $2.2 billion in fiscal 2016.


     

  • [By Ben Levisohn]

    My colleague Tiernan Rey at Barron’s Tech Trader Daily quoted B. Rileys Craig Ellis in a post today, who called the selloff yesterday an unusually attractive entry opportunity forApplied Materials andMicrochip Technology (MCHP) buyers.

Top 5 Medical Stocks To Buy For 2018: Arcadia Biosciences, Inc.(RKDA)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q3 2016 earnings report formid cap pet stock agricultural biotechnology Arcadia Biosciences (NASDAQ: RKDA) is scheduled for after the market closes onThursday (November 10th). Last Thursday, our Under the Radar Movers newsletter suggestedthe stockas a short/bearish trade, saying:

  • [By Jim Robertson]

    Yesterday, our Under the Radar Movers newsletter suggested small cap agricultural biotechnology Arcadia Biosciences (NASDAQ: RKDA) as a short/bearish trade:

Top 5 Medical Stocks To Buy For 2018: Astro-Med, Inc.(ALOT)


Advisors’ Opinion:

  • [By Monica Gerson]

    Astro-Med, Inc. (NASDAQ: ALOT) is projected to post its quarterly earnings at $0.21 per share on revenue of $25.50 million.

    Bellatrix Exploration Ltd (NYSE: BXE) is expected to post a quarterly loss at $0.10 per share on revenue of $71.27 million.

Top 5 Medical Stocks To Buy For 2018: Insys Therapeutics, Inc.(INSY)

Advisors’ Opinion:

  • [By Keith Speights]

    There are plenty of reasons for investors to like three marijuana stocks in particular — GW Pharmaceuticals (NASDAQ:GWPH), Insys Therapeutics (NASDAQ:INSY), and Aphria (NASDAQOTH:APHQF). In fact, there are at least 661 million reasons. That’s the amount of cash in U.S. dollars that the three companies have combined. Here’s why the cash stockpiles held by GW, Insys, and Apria are important.

  • [By William Patalon III]

    Insys Therapeutics Inc. (NASDAQ: INSY) – our “War on Pain” biotech play – has given us a profit of more than 16% since we recommended the stock just two weeks ago.

  • [By Ashley Moore]

    We’ve compiled a list of the most heavily shorted stocks to show you which stocks have the most negative sentiment on the market…

    Company Name (Ticker)Short FloatShare PriceHanwha Q Cells Co. Ltd. (Nasdaq ADR: HQCL)98.52%$ 8.88Renren Inc. (NYSE: RENN)91.59%$ 8.53Weight Watchers International Inc. (NYSE: WTW)67.92%$12.57INSYS Therapeutics Inc. (Nasdaq: INSY)66.71%$10.74Twilio Inc. (NYSE: TWLO)66.34%$33.17Nutanix Inc. (Nasdaq: NTNX)65.65%$31.96Fitbit Inc. (NYSE: FIT)55.15%$ 6.06Weibo Corp. (Nasdaq ADR: WB)53.83%$55.26RPC Inc. (NYSE: RES)53.62%$21.19Straight Path Communications Inc. (NYSEMKT: STRP)49.27%$34.79Momo Inc. (Nasdaq ADR: MOMO)48.63%$26.80Seritage Growth Properties (NYSE: SRG)46.91%$44.87Lannett Company Inc. (NYSE: LCI)45.46%$23.00Gogo Inc. (Nasdaq: GOGO)43.98%$ 9.10Altisource Portfolio Solutions SA (Nasdaq: ASPS)42.78%$22.73Cheetah Mobile Inc. (NYSE ADR: CMCM)40.86%$10.00


    Some investors think the only way to profit from the stock market is to buy stocks and wait for the price to rise. However, these investors are missing out on the massive profit opportunity that comes from shorting stocks.

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell by 0.20 percent. Meanwhile, top losers in the sector included Horizon Pharma PLC (NASDAQ: HZNP), down 20 percent, and Insys Therapeutics Inc (NASDAQ: INSY), down 17 percent.

Top 5 Medical Stocks To Buy For 2018: Cherokee Inc.(CHKE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cherokee Inc (NASDAQ: CHKE) shares dropped 37 percent to $4.85 after the company reported a loss for its first quarter on Thursday. The company reported an adjusted loss of $0.07 per share, versus analysts’ estimates for a profit of $0.13 per share.

  • [By Lisa Levin]

    Cherokee Inc (NASDAQ: CHKE) shares dropped 32 percent to $5.26 after the company reported a loss for its first quarter on Thursday. The company reported an adjusted loss of $0.07 per share, versus analysts’ estimates for a profit of $0.13 per share.

Leave a Reply

Your email address will not be published. Required fields are marked *